A single-blind, nonrandomized, placebo crossover clinical trial of an aldose reductase inhibitor, Alrestatin (AY 22, 284) was performed over a 4-mo period in nine patients with diabetic peripheral neuropathy. Most patients had subjective benefit, but objective measures of conduction were essentially unchanged. Substantial toxicity was evident, particularly photosensitive skin rash.

Zusammenfassung: Von 12 normalen Miinnern (Gruppe A) und 8 infertilen Miinnern mit Oligozoospennie bei Spermatozoenkonzentrationen von weniger als 20 x lo6 /ml (Gruppe B) wurden Samenproben (Split-und vollstiindige Ejakulate) untersucht. M e Samenproben wurden untersucht mit StandardSamen Analyse, Rinderzervikalschleim-Penetrationsassay (CMPT) und in allen Fiillen mit hinreichendem Samen im Hmanspermatozoen-zonafreiesHamsterei-Penetrationsassay (SPA).

Detection of heterozygote carriers for congenital adrenal hyperplasia by use of a modified tetracosactide (a synthetic corticotropin) stimulation test with prior overnight dexamethasone suppression proved to have a diagnostic accuracy of 95%. Discrimination of heterozygotes from normals was best when we used a criterion based on the ratios of 17 alpha-hydroxyprogesterone to cortisol at baseline and at 30 min after intravenous administration of 250 micrograms of tetracosactide.